TORONTO, Nov. 1, 2018 /CNW/ - Pure Global Cannabis Inc. (TSX.V:PURE; OTC: PRCNF; FRA:1QS) (the "Company" or "Pure Global" or "PURE"), an integrated, growth-oriented life sciences cannabis company, through its subsidiary PureSinse Inc. ("PureSinse"), is pleased to announce that it has made three new hires to help with company's operations and the production of expanded PureSinse offerings: Sandra Couto as Clinical Affairs Lead, Cheryl Pim as Director of New Product Development, and Joseph Choi as Controller.
Sandra, Cheryl, and Joseph will serve as integral members of the senior leadership team. Their skills and expertise will become vital to the operations and further development of the company's initiatives and products.
Pure Global's new Clinical Affairs Lead, Sandra Couto, has been a driving force in the Canadian pharmaceutical sector for more than twenty years. Couto, a trained pharmacist, has held senior positions at University Health Network, Schering Plough, Janssen Ortho, Solvay, Wyeth Ayerst, and Dupont, having worked in product management, sales, clinical trials, and stakeholder relations. She will drive the clinical and scientific objectives of Pure Global's investigational and medical partnership programs. Sandra will also build a cross-functional clinical portfolio of relationships internally and with external partners.
Cheryl Pim joins Pure Global as the Director of New Product Development. She is an award-winning senior marketing and sales leader, product developer, and strategic planner having held senior positions for Abbott, Janssen-Ortho, Allergan, and Astellas. Cheryl will lead and coordinate the design, launch and management of a range of pharmaceutical, cosmetic, and health and wellness products. She will use her experience in product design and marketing to create unique products in categories where Pure Global can take a leadership position.
Joseph Choi brings a strong background in finance to the role of Controller at Pure Global. He has more than five years' experience as a financial professional in the cannabis industry. In his position, Choi will report to the Chief Financial Officer, add strategic vision, and be instrumental in deploying comprehensive and scalable corporate accounting and financial management systems. Joseph has experience working with publicly traded licensed producers of cannabis and will ensure timely and accurate accounting and preparation of financial reports across all business units.
"I am thrilled to be adding such talented individuals to our high-caliber team and adding significant bandwidth to our clinical and product development capabilities," said Malay Panchal, CEO of Pure Global. "This will enhance and expedite Pure Global's ability to deploy a range of pharmaceutical, nutraceutical, and health & wellness products to meet the needs of the Canadian and growing international markets."
About Pure Global Cannabis
Pure Global Cannabis Inc. (TSX.V:PURE; OTC:PRCNF; FRA:1QS) is an innovation-based cannabis Company led by experienced pharma, biotechnology, horticultural, consumer packaged goods (CPG), and supply chain experts. The Company's wholly owned subsidiary, PureSinse Inc., is a licensed producer under the Cannabis Act, 2017. The Company's Brampton campus houses facilities for vertically farmed cultivation, R&D, extraction, manufacturing, and distribution. PURE will produce branded and white-labeled cannabis products for the medical, pharmaceutical, wellness, health & beauty, natural health, food & beverage, and recreational legal markets with uniquely formulated and purified concentrates. The Company is using the Canadian market as a springboard to develop and manufacture GMP-compliant cannabis products for international sale and distribution with a goal to become one of the most trusted premium international cannabis brands.
This news release contains certain forward-looking statements, including, but not limited to, statements about Pure Global's future plans and intentions. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this news release are based upon what management believes to be reasonable assumptions, Pure Global cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release, and Pure Global assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Pure Global Cannabis Inc.
For further information: regarding Pure Global, please contact: Stephen Pynn, VP Corporate Development, Telephone: 1-866-899-PURE (7873), E-mail: [email protected]; Malay (Mel) Panchal, President & CEO, Telephone: 1-866-899-PURE (7873), E-mail: [email protected]